Overview of the Trial Results#
Shares of Greenwich LifeSciences (NASDAQ:GLSI) increased by over 4% in premarket trading on Monday following the announcement of encouraging results from its breast cancer vaccine trial. The company reported that its experimental vaccine, GLSI-100, demonstrated a significant immune response in patients participating in the late-stage FLAMINGO-01 study.
Vaccine's Purpose and Target#
The GLSI-100 vaccine aims to prevent the recurrence of breast cancer after standard treatment. It specifically targets HER2-positive breast cancer, which is known to be an aggressive form of the disease with a higher likelihood of returning after treatment.
Immune Response Findings#
According to Greenwich LifeSciences, patients who lack a specific immune system gene called HLA-A02 showed an increase in immune response from 5.2% at the beginning of the trial to 20.4% after receiving the vaccine. This indicates a notable enhancement in the body’s ability to fight off potential cancer recurrence.
Reduction in Recurrence Rates#
The company also reported that breast cancer recurrence in this particular patient group decreased by up to 80% following the initial series of vaccine injections. These findings are consistent with earlier results from the trial, reinforcing the vaccine's potential effectiveness.
Future Steps#
Greenwich LifeSciences mentioned that it may pursue regulatory approval for the vaccine in both genetic subgroups, depending on the final outcomes of the trial. This could pave the way for broader access to the vaccine for patients at risk of HER2-positive breast cancer recurrence.